BACKGROUND: We observed an increased rate of Pseudomonas aeruginosa bacteremia in our hematology unit in 2004-2007 without an identified environmental source. METHODS: We conducted a matched case-control study to investigate factors associated with P aeruginosa bacteremia in patients with hematologic malignancies. RESULTS: Forty-two episodes of P aeruginosa bacteremia were identified. At presentation, 26 patients (62%) had pneumonia and 9 patients (21%) were in shock. Twenty-five patients (60%) were aplastic. The clinical cure rate was 40%. Comparing the 42 cases with 84 matched controls identified the following independent risk factors for P aeruginosa bacteremia: hospitalization in the previous 3 months (odds ratio [OR], 12.84; 95% confidence interval [CI], 2.98-55.18), antibiotic therapy in the previous 3 months (OR, 5.34; 95% CI, 2.14-13.30), receipt of ceftriaxone in the previous 3 months (OR, 2.38; 95% CI, 1.08-5.27), receipt of aminoglycosides in the previous 3 months (OR, 6.65; 95% CI, 1.15-38.25) and receipt of fluoroquinolones in the previous 3 months (OR, 3.22; 95% CI, 1.48-7.00). CONCLUSIONS: Local antibiotic therapy algorithms were modified to decrease prescriptions of ceftriaxone and combination therapy with aminoglycosides and fluoroquinolones in an effort to decrease the risk of P aeruginosa bacteremia.
BACKGROUND: We observed an increased rate of Pseudomonas aeruginosa bacteremia in our hematology unit in 2004-2007 without an identified environmental source. METHODS: We conducted a matched case-control study to investigate factors associated with P aeruginosa bacteremia in patients with hematologic malignancies. RESULTS: Forty-two episodes of P aeruginosa bacteremia were identified. At presentation, 26 patients (62%) had pneumonia and 9 patients (21%) were in shock. Twenty-five patients (60%) were aplastic. The clinical cure rate was 40%. Comparing the 42 cases with 84 matched controls identified the following independent risk factors for P aeruginosa bacteremia: hospitalization in the previous 3 months (odds ratio [OR], 12.84; 95% confidence interval [CI], 2.98-55.18), antibiotic therapy in the previous 3 months (OR, 5.34; 95% CI, 2.14-13.30), receipt of ceftriaxone in the previous 3 months (OR, 2.38; 95% CI, 1.08-5.27), receipt of aminoglycosides in the previous 3 months (OR, 6.65; 95% CI, 1.15-38.25) and receipt of fluoroquinolones in the previous 3 months (OR, 3.22; 95% CI, 1.48-7.00). CONCLUSIONS: Local antibiotic therapy algorithms were modified to decrease prescriptions of ceftriaxone and combination therapy with aminoglycosides and fluoroquinolones in an effort to decrease the risk of P aeruginosa bacteremia.
Authors: Adaia Albasanz-Puig; Xavier Durà-Miralles; Júlia Laporte-Amargós; Alberto Mussetti; Isabel Ruiz-Camps; Pedro Puerta-Alcalde; Edson Abdala; Chiara Oltolini; Murat Akova; José Miguel Montejo; Malgorzata Mikulska; Pilar Martín-Dávila; Fabián Herrera; Oriol Gasch; Lubos Drgona; Hugo Manuel Paz Morales; Anne-Sophie Brunel; Estefanía García; Burcu Isler; Winfried V Kern; Pilar Retamar-Gentil; José María Aguado; Milagros Montero; Souha S Kanj; Oguz R Sipahi; Sebnem Calik; Ignacio Márquez-Gómez; Jorge I Marin; Marisa Z R Gomes; Philipp Hemmati; Rafael Araos; Maddalena Peghin; José Luis Del Pozo; Lucrecia Yáñez; Robert Tilley; Adriana Manzur; Andres Novo; Natàlia Pallarès; Alba Bergas; Jordi Carratalà; Carlota Gudiol Journal: Microorganisms Date: 2022-03-29
Authors: Ji Hwan Bang; Younghee Jung; Shinhye Cheon; Chung Jong Kim; Kyung Ho Song; Pyeong Gyun Choe; Wan Beom Park; Eu Suk Kim; Sang Won Park; Hong Bin Kim; Myoung-don Oh; Hyo-Suk Lee; Nam Joong Kim Journal: BMC Infect Dis Date: 2013-07-19 Impact factor: 3.090